- Home
- CELH vs BMRN Comparison
CELH vs BMRN Comparison
Compare CELH & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- BMRN
- Stock Information
- Founded
- CELH 2004
- BMRN 1996
- Country
- CELH United States
- BMRN United States
- Employees
- CELH N/A
- BMRN N/A
- Industry
- CELH Beverages (Production/Distribution)
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- BMRN Health Care
- Exchange
- CELH Nasdaq
- BMRN Nasdaq
- Market Cap
- CELH 15.3B
- BMRN 10.0B
- IPO Year
- CELH N/A
- BMRN 1999
- Fundamental
- Price
- CELH $41.73
- BMRN $51.52
- Analyst Decision
- CELH Strong Buy
- BMRN Buy
- Analyst Count
- CELH 18
- BMRN 19
- Target Price
- CELH $62.39
- BMRN $90.26
- AVG Volume (30 Days)
- CELH 6.5M
- BMRN 2.8M
- Earning Date
- CELH 11-06-2025
- BMRN 10-27-2025
- Dividend Yield
- CELH N/A
- BMRN N/A
- EPS Growth
- CELH N/A
- BMRN 59.53
- EPS
- CELH 0.13
- BMRN 2.68
- Revenue
- CELH $2,125,838,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- CELH $85.38
- BMRN $13.32
- Revenue Next Year
- CELH $31.08
- BMRN $7.51
- P/E Ratio
- CELH $326.14
- BMRN $19.20
- Revenue Growth
- CELH 55.07
- BMRN 12.39
- 52 Week Low
- CELH $21.10
- BMRN $50.76
- 52 Week High
- CELH $66.74
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- CELH 18.33
- BMRN 40.53
- Support Level
- CELH $56.96
- BMRN $51.80
- Resistance Level
- CELH $61.49
- BMRN $53.49
- Average True Range (ATR)
- CELH 2.70
- BMRN 1.84
- MACD
- CELH -2.24
- BMRN -0.08
- Stochastic Oscillator
- CELH 5.19
- BMRN 12.58
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.